|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM293990891 |
| 003 |
DE-627 |
| 005 |
20231225080524.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2019 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.201803322
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0979.xml
|
| 035 |
|
|
|a (DE-627)NLM293990891
|
| 035 |
|
|
|a (NLM)30773696
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Phuengkham, Hathaichanok
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy
|
| 264 |
|
1 |
|c 2019
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 12.09.2019
|
| 500 |
|
|
|a Date Revised 04.12.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
|
| 520 |
|
|
|a Cancer immunotherapies that harness the body's immune system to combat tumors have received extensive attention and become mainstream strategies for treating cancer. Despite promising results, some problems remain, such as the limited patient response rate and the emergence of severe immune-related adverse effects. For most patients, the therapeutic efficacy of cancer immunotherapy is mainly limited by the immunosuppressive tumor microenvironment (TME). To overcome such obstacles in the TME, the immunomodulation of immunosuppressive factors and therapeutic immune cells (e.g., T cells and antigen-presenting cells) should be carefully designed and evaluated. Nanoengineered synthetic immune niches have emerged as highly customizable platforms with a potent capability for reprogramming the immunosuppressive TME. Here, recent developments in nano-biomaterials that are rationally designed to modulate the immunosuppressive TME in a spatiotemporal manner for enhanced cancer immunotherapy which are rationally designed to modulate the immunosuppressive TME in a spatiotemporal manner for enhanced cancer immunotherapy are highlighted
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a antitumor immunity
|
| 650 |
|
4 |
|a cancer immunotherapy
|
| 650 |
|
4 |
|a immunosuppression
|
| 650 |
|
4 |
|a nanoengineered immune niches
|
| 650 |
|
4 |
|a tumor microenvironment
|
| 650 |
|
7 |
|a Cancer Vaccines
|2 NLM
|
| 700 |
1 |
|
|a Ren, Long
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shin, Il Woo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lim, Yong Taik
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 31(2019), 34 vom: 30. Aug., Seite e1803322
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:31
|g year:2019
|g number:34
|g day:30
|g month:08
|g pages:e1803322
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.201803322
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 31
|j 2019
|e 34
|b 30
|c 08
|h e1803322
|